drugset / Trial / NCT02462109

Catatonia in Nodding Syndrome and Lorazepam Treatment

NCT02462109

NaSingle-groupOpen-labelSupportive care

Summary

Nodding Syndrome is an enigmatic neuropsychiatric syndrome affecting children and adolescents mostly in Eastern Africa. The symptoms of Nodding Syndrome and catatonia seem to overlap. The researchers' objectives in this study were to investigate the presence and types of catatonic symptoms in children with Nodding Syndrome and observe their response to one or two doses of lorazepam, the first-line treatment for catatonia.

Timeline

Start
2013-03
Primary completion
2013-03
Completion
2013-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 0.5 mg Oral
Subject Lorazepam Small molecule 1 mg Oral

Indications